Standout Papers

Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): l... 2022 2026 2023 2024169
  1. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial (2022)
    Robert J. Motzer, Thomas Powles et al. The Lancet Oncology

Immediate Impact

3 by Nobel laureates 10 from Science/Nature 59 standout
Sub-graph 1 of 21

Citing Papers

Renal cell carcinoma
2024 Standout
Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma
2023 Standout
1 intermediate paper

Works of Christian Scheffold being referenced

Nivolumab plus ipilimumab plus cabozantinib triplet combination for patients with previously untreated advanced renal cell carcinoma: Results from a discontinued arm of the phase III CheckMate 9ER trial
2022
397 Phase 2 results of XL184 in a cohort of patients (pts) with advanced non-small cell lung cancer (NSCLC)
2010
and 4 more

Author Peers

Author Last Decade Papers Cites
Christian Scheffold 991 1022 865 74 2.2k
Thomas A. Puchalski 822 1523 895 50 2.8k
Susan C. Guba 764 1288 658 49 2.3k
Irene Braña 581 1236 1241 134 2.5k
Alison M. Schram 841 1048 1034 89 2.8k
Todd Hembrough 512 859 924 70 2.2k
Ki Y. Chung 696 1601 606 61 2.3k
Heike Richly 719 1135 1059 56 2.3k
Wael A. Harb 740 1366 903 117 2.4k
Marta Salido 747 1253 694 110 2.4k
Iacopo Petrini 695 985 861 88 2.4k

All Works

Loading papers...

Rankless by CCL
2026